カテゴリ： GlobalData, アイルランド, 企業調査

Horizon Pharma Plc (HZNP)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Horizon Pharma Plc (HZNP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9854
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：102
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アイルランド
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Horizon Pharma plc (Horizon Pharma) is a pharmaceutical company which develops and commercializes medical products for the treatment of pain, arthritis and inflammatory diseases. It markets medicines through its orphan, primary care and rheumatology business units. The company’s marketed products include Actimmune, Buphenyl, Duexis, Krystexxa, Migergot, Pennsaid 2%, Procysbi, Quinsair, Ravicti, Rayos and Vimovo. Horizon Pharma provides products and services to patients and healthcare professionals in the US. The company operates through offices in Illinois, California, Switzerland, the Netherlands and Germany. Horizon Pharma is headquartered in Dublin, Ireland.

Horizon Pharma Plc (HZNP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Horizon Pharma Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
Horizon Pharma Acquires Worldwide Rights to Interferon Gamma-1b from Boehringer Ingelheim for USD28.2 Million 15
Horizon Pharma Acquires US Rights to Pennsaid 2% from Nuvo Research for USD45 Million 16
Hyperion Therapeutics Completes Acquisition Of Rights To Buphenyl And Ammonul From Ucyclyd Pharma For US$51 Million 18
Vidara Therapeutics International Acquires Actimmune From InterMune For US$55 Million 20
Hyperion Therapeutics Acquires Rights Of Ravicti From Ucyclyd Pharma 22
Venture Financing 23
River Vision Development Raises USD5 Million in Financing Round 23
River Vision Development Raises USD5.3 Million in Financing Round 24
River Vision Development Raises USD6 Million in Financing Round 25
River Vision Development Raises US$17 Million In Series A Financing 26
Hyperion Therapeutics Raises US$15 Million In Series D-II Financing 27
Private Equity 28
Vidara Therapeutics Raises Funds Through Private Equity Financing 28
Partnerships 29
Horizon Pharma Enters into Agreement with XL-protein 29
Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ravicti 30
Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ammonaps 31
Clinigen Group Partners with Horizon Pharma 32
Horizon Pharma Enters into Agreement with Alliance for Lupus Research 33
Horizon Pharma And Mundipharma Amend Distribution Agreement For Lodotra 34
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Hyperion Therapeutics 36
Mallinckrodt Enters Into Co-Promotion Agreement With Horizon Pharma For Duexis 37
Horizon Pharma Amends Co-Marketing Agreement With Mundipharma International For LODOTRA 38
Licensing Agreements 40
Horizon Pharma Enters into Licensing Agreement with MedImmune for MEDI4945 40
Horizon Pharma Enters into Licensing Agreement for Interferon Gamma-1b 41
Grunenthal Enters Into Licensing Agreement With Horizon Pharma For Duexis 42
Equity Offering 43
Horizon Pharma Raises USD499 million in Public Offering of Shares 43
Hyperion Therapeutics Files Registration Statement For Public Offering Of Securities For $150 Million 45
Hyperion Therapeutics Completes Public Offering Of Common Stock For US$69 Million 46
Horizon Pharma Completes Public Offering Of Units For US$86 Million 47
Hyperion Therapeutics Completes IPO For US$57.5 Million 48
Horizon Pharma Completes Private Placement Of Units For US$51 Million 49
Debt Offering 50
Horizon Pharma Raises USD300 Million in Private Placement of 8.75% Notes Due 2024 50
Horizon Pharma Raises USD475 Million in Private Placement of 6.625% Notes Due 2023 51
Horizon Pharma Raises USD400 Million in Private Placement of 2.5% Senior Notes Due 2022 53
Horizon Pharma Completes Private Placement Of Notes Due 2018 For US$150 Million 55
Asset Transactions 56
Clinigen Acquires Imukin from Horizon Pharma 56
Horizon Pharma May Sell its Primary Care Drugs Business 57
Horizon Pharma Sells PROCYSBI and QUINSAIR to Chiesi Farmaceutici 58
Acquisition 59
Horizon Pharma Acquires River Vision Development 59
Horizon Pharma Acquires Raptor Pharma in Tender Offer 60
Horizon Pharma May Sell Equity Stake in The Company 62
Horizon Pharma Acquires Crealta for USD510 Million 63
Horizon Pharma Acquires Hyperion Therapeutics for USD1.1 Billion 64
Horizon Pharma Acquires Vidara Therapeutics International for USD660 Million in Reverse Acquisition 66
Horizon Pharma Plc – Key Competitors 68
Horizon Pharma Plc – Key Employees 69
Horizon Pharma Plc – Locations And Subsidiaries 70
Head Office 70
Other Locations & Subsidiaries 70
Recent Developments 71
Financial Announcements 71
Nov 07, 2018: Horizon pharma reports third-quarter net sales growth of 20 percent driven by Orphan and Rheumatology net sales growth of 25 percent 71
Aug 08, 2018: Horizon pharma reports record quarterly net sales for orphan and rheumatology segment; increases full-year 2018 adjusted EBITDA guidance; implements new company operating structure to enhance focus on rare diseases 73
May 09, 2018: Horizon Pharma Reports Strong First-Quarter 2018 Orphan and Rheumatology Net Sales Growth 76
Feb 28, 2018: Horizon Pharma Announces Fourth-Quarter and Full-Year 2017 Results 79
Nov 06, 2017: Horizon Pharma Announces Third-Quarter and Year-to-Date 2017 Results 83
Aug 07, 2017: Horizon Pharma Announces Second-Quarter and Year-to-Date 2017 Results and Increases Full-Year 2017 Net Sales and Adjusted EBITDA Guidance 86
May 08, 2017: Horizon Pharma Announces First-Quarter 2017 Results and Revises Full-Year 2017 Net Sales and Adjusted EBITDA Guidance 90
Corporate Communications 93
Nov 30, 2017: Horizon Pharma Names Shao-Lee Lin, M.D., Ph.D. Executive Vice President, Research and Development and Chief Scientific Officer 93
Sep 11, 2017: Horizon Pharma Names Irina Konstantinovsky Executive Vice President, Chief Human Resources Officer 94
Aug 03, 2017: Horizon Pharma Appoints Pascale Witz and James Shannon, M.D. to Board of Directors 95
Other Significant Developments 96
Sep 27, 2018: The north american pediatric renal trials and collaborative studies and Horizon Pharma announce new long-term cystinosis registry 96
Jun 04, 2018: Horizon Pharma and the National Organization for Rare Disorders (NORD) Illustrate 35 years of Progress in Rare Disease at the Biotechnology Innovation Organization (BIO) International Convention 97
Jan 08, 2018: Horizon Pharma Increases Peak Net Sales Guidance for Key Growth Drivers and Announces Rheumatology and Orphan Pipeline Developments 98
Mar 16, 2017: Horizon Pharma Announces “UCD in Common” for the Urea Cycle Disorder Community 101
Appendix 102
Methodology 102
About GlobalData 102
Contact Us 102
Disclaimer 102

List of Tables
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Horizon Pharma Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Horizon Pharma Plc, Deals By Therapy Area, 2012 to YTD 2018 10
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Horizon Pharma Acquires Worldwide Rights to Interferon Gamma-1b from Boehringer Ingelheim for USD28.2 Million 15
Horizon Pharma Acquires US Rights to Pennsaid 2% from Nuvo Research for USD45 Million 16
Hyperion Therapeutics Completes Acquisition Of Rights To Buphenyl And Ammonul From Ucyclyd Pharma For US$51 Million 18
Vidara Therapeutics International Acquires Actimmune From InterMune For US$55 Million 20
Hyperion Therapeutics Acquires Rights Of Ravicti From Ucyclyd Pharma 22
River Vision Development Raises USD5 Million in Financing Round 23
River Vision Development Raises USD5.3 Million in Financing Round 24
River Vision Development Raises USD6 Million in Financing Round 25
River Vision Development Raises US$17 Million In Series A Financing 26
Hyperion Therapeutics Raises US$15 Million In Series D-II Financing 27
Vidara Therapeutics Raises Funds Through Private Equity Financing 28
Horizon Pharma Enters into Agreement with XL-protein 29
Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ravicti 30
Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ammonaps 31
Clinigen Group Partners with Horizon Pharma 32
Horizon Pharma Enters into Agreement with Alliance for Lupus Research 33
Horizon Pharma And Mundipharma Amend Distribution Agreement For Lodotra 34
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Hyperion Therapeutics 36
Mallinckrodt Enters Into Co-Promotion Agreement With Horizon Pharma For Duexis 37
Horizon Pharma Amends Co-Marketing Agreement With Mundipharma International For LODOTRA 38
Horizon Pharma Enters into Licensing Agreement with MedImmune for MEDI4945 40
Horizon Pharma Enters into Licensing Agreement for Interferon Gamma-1b 41
Grunenthal Enters Into Licensing Agreement With Horizon Pharma For Duexis 42
Horizon Pharma Raises USD499 million in Public Offering of Shares 43
Hyperion Therapeutics Files Registration Statement For Public Offering Of Securities For $150 Million 45
Hyperion Therapeutics Completes Public Offering Of Common Stock For US$69 Million 46
Horizon Pharma Completes Public Offering Of Units For US$86 Million 47
Hyperion Therapeutics Completes IPO For US$57.5 Million 48
Horizon Pharma Completes Private Placement Of Units For US$51 Million 49
Horizon Pharma Raises USD300 Million in Private Placement of 8.75% Notes Due 2024 50
Horizon Pharma Raises USD475 Million in Private Placement of 6.625% Notes Due 2023 51
Horizon Pharma Raises USD400 Million in Private Placement of 2.5% Senior Notes Due 2022 53
Horizon Pharma Completes Private Placement Of Notes Due 2018 For US$150 Million 55
Clinigen Acquires Imukin from Horizon Pharma 56
Horizon Pharma May Sell its Primary Care Drugs Business 57
Horizon Pharma Sells PROCYSBI and QUINSAIR to Chiesi Farmaceutici 58
Horizon Pharma Acquires River Vision Development 59
Horizon Pharma Acquires Raptor Pharma in Tender Offer 60
Horizon Pharma May Sell Equity Stake in The Company 62
Horizon Pharma Acquires Crealta for USD510 Million 63
Horizon Pharma Acquires Hyperion Therapeutics for USD1.1 Billion 64
Horizon Pharma Acquires Vidara Therapeutics International for USD660 Million in Reverse Acquisition 66
Horizon Pharma Plc, Key Competitors 68
Horizon Pharma Plc, Key Employees 69
Horizon Pharma Plc, Subsidiaries 70

List of Figures
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

★海外企業調査レポート[Horizon Pharma Plc (HZNP)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Danville Materials Inc：医療機器：M&Aディール及び事業提携情報
    Summary Danville Materials Inc (Danville), a subsidiary of Inverness Graham Investments is a medical device company that manufactures dental equipment. The company provides posts, air abrasion, tin plating, adhesives, sand blasting, composites, air polishing, dust cabinets, microetcher, and IPR. It …
  • PT. Indonesia Power：企業の戦略的SWOT分析
    PT. Indonesia Power - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Centrais Eletricas Brasileiras S.A. (ELET6)：電力：M&Aディール及び事業提携情報
    Summary Centrais Eletricas Brasileiras S.A. (Eletrobras) is an electric utility. It generates, transmits, and distributes energy. The company produces electricity from hydro, nuclear, wind, natural gas, oil, coal, solar, and biomass sources. Eletrobras promotes the Latin American electric integratio …
  • Targa Resources Partners LP (NGLS PR A)：石油・ガス：M&Aディール及び事業提携情報
    Summary Targa Resources Partners LP (Targa Resources) is an independent midstream company. It carries out the gathering, compressing, treating, processing and sale of natural gas, and storing, fractionating, treating, transporting and selling natural gas liquids (NGLs) and NGL products. The company …
  • Protagonist Therapeutics Inc (PTGX)：製薬・医療：M&Aディール及び事業提携情報
    Summary Protagonist Therapeutics Inc (Protagonist) is a clinical-stage biopharmaceutical company that discovers and develops orally stable peptides as targeted therapies. The company through its proprietary technology platform develops structurally novel oral or injectable peptides for protein-prote …
  • EPAM Systems Inc (EPAM)：企業の財務・戦略的SWOT分析
    EPAM Systems Inc (EPAM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Centre for Drug Design and Discovery-製薬・医療分野：企業M&A・提携分析
    Summary Centre for Drug Design and Discovery (CD3) is a biomedical research institution that discovers new small molecule drugs. The institution provides services such as silico molecule design, modelling and screening, medicinal chemistry, intellectual property rights support, business development, …
  • Bulgarian Telecommunications Company (VIVACOM)：企業の戦略的SWOT分析
    Bulgarian Telecommunications Company (VIVACOM) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitor …
  • FDM Group (Holdings) plc (FDM)：企業の財務・戦略的SWOT分析
    FDM Group (Holdings) plc (FDM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Alamo Group, Inc.：戦略・SWOT・企業財務分析
    Alamo Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Alamo Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Narada Power Source Co Ltd (300068)：企業の財務・戦略的SWOT分析
    Summary Narada Power Source Co Ltd (Narada Power) is a battery manufacturer and distributor that markets and supplies stored energy solutions. The company's products include eos series batteries, acme series, acmeG series, GP series, TTG series, TT series, eosG series, GPG series, MP series, HRL ser …
  • Intracom Holdings SA (INTRK)：企業の財務・戦略的SWOT分析
    Intracom Holdings SA (INTRK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • APR Energy Ltd：電力：M&Aディール及び事業提携情報
    Summary APR Energy Ltd (APR), formerly APR Energy plc, is an energy solutions and services provider. The company installs, owns, operates and maintains power plants for applications such as bridging power, distributed power, grid stability and support, emergency power, industrial generation and peak …
  • China UnionPay Company Ltd：企業の戦略・SWOT・財務情報
    China UnionPay Company Ltd - Strategy, SWOT and Corporate Finance Report Summary China UnionPay Company Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • AusGroup Ltd (5GJ)：企業の財務・戦略的SWOT分析
    Summary AusGroup Ltd (AusGroup) is a provider of project and asset services. The company operates through its subsidiaries, namely, MAS, AGC, and NT Port and Marine. Its major services include mechanical and piping, scaffolding, multidisciplinary maintenance services, fabrication & management, elect …
  • Ultimovacs AS-製薬・医療分野：企業M&A・提携分析
    Summary Ultimovacs AS (Ultimovacs) is a provider of novel immunotherapies for cancer treatment. The company develops synthetic peptide based therapeutic vaccines that can be used on its own and also in combination with conventional therapies such as surgery, chemotherapy, and irradiation. Its UV1 is …
  • Hareon Solar Technology Co Ltd (600401)：電力：M&Aディール及び事業提携情報
    Summary Hareon Solar Technology Co Ltd (Hareon Solar) is a renewable energy company that manufactures and markets solar energy products. The company offers silicon cells and solar modules. Its products portfolio includes mono crystalline silicon solar cells, poly crystalline silicon solar cells, pol …
  • Telekom Austria AG：企業の戦略・SWOT・財務情報
    Telekom Austria AG - Strategy, SWOT and Corporate Finance Report Summary Telekom Austria AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Pearson plc：企業の戦略・SWOT・財務情報
    Pearson plc - Strategy, SWOT and Corporate Finance Report Summary Pearson plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • NBCUniversal Media LLC：企業のM&A・事業提携・投資動向
    NBCUniversal Media LLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's NBCUniversal Media LLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆